;PMID: 1581907
;source_file_474.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)sentence:[e:0..151] = [t:0..151]
;1)section:[e:155..219] = [t:155..219]
;2)sentence:[e:223..305] = [t:223..305]
;3)sentence:[e:309..539] = [t:309..539]
;4)sentence:[e:541..691] = [t:541..691]
;5)sentence:[e:692..731] = [t:692..731]
;6)sentence:[e:732..809] = [t:732..809]
;7)sentence:[e:810..992] = [t:810..992]
;8)sentence:[e:993..1068] = [t:993..1068]
;9)sentence:[e:1069..1303] = [t:1069..1303]
;10)sentence:[e:1304..1427] = [t:1304..1427]
;11)section:[e:1431..1475] = [t:1431..1475]

;sentence 0 Span:0..151
;Cancer Res  1992 May 15;52(10):2903-6     ras gene mutations as a prognostic
;marker in adenocarcinoma of the human lung  without lymph node metastasis.
;[42..45]:gene-rna:"ras"
;[87..119]:malignancy:"adenocarcinoma of the human lung"
;[129..150]:malignancy:"lymph node metastasis"
(SENT
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1992)
        (NNP:[17..20] May) (CD:[21..23] 15) (CD:[23..25] ;5) (CD:[25..26] 2)
        (NN:[26..27] -LRB-) (NN:[27..29] 10) (NN:[29..30] -RRB-) (::[30..31] :)
        (CD:[31..34] 290) (JJ:[34..37] 3-6))
  (NP-HLN
    (NP (NN:[42..45] ras) (NN:[46..50] gene) (NNS:[51..60] mutations))
    (PP (IN:[61..63] as)
      (NP (DT:[64..65] a) (JJ:[66..76] prognostic) (NN:[77..83] marker)))
    (PP (IN:[84..86] in)
      (NP
        
        (NP (NN:[87..101] adenocarcinoma))
        (PP (IN:[102..104] of)
          (NP (DT:[105..108] the) (JJ:[109..114] human) (NN:[115..119] lung)))
        (PP (IN:[121..128] without)
          (NP
            (NML (NN:[129..134] lymph) (NN:[135..139] node))
            (NN:[140..150] metastasis)))))
    (.:[150..151] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[0..151]::FRAG:NP:

;section 1 Span:155..219
;Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T.
(SEC
  (FRAG (NNP:[155..160] Sugio) (NNP:[161..163] K,) (NNP:[164..170] Ishida)
        (NNP:[171..172] T) (,:[172..173] ,) (NNP:[174..182] Yokoyama)
        (NNP:[183..185] H,) (NNP:[186..191] Inoue) (NNP:[192..193] T)
        (,:[193..194] ,) (NNP:[195..204] Sugimachi) (NNP:[205..207] K,)
        (NNP:[208..216] Sasazuki) (NNP:[217..219] T.)))

;sentence 2 Span:223..305
;Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, 
;Japan.
(SENT
  (FRAG (NNP:[223..233] Department) (IN:[234..236] of) (NNP:[237..244] Surgery)
        (NNP:[245..247] II) (,:[247..248] ,) (NNP:[249..256] Faculty)
        (IN:[257..259] of) (NNP:[260..268] Medicine) (,:[268..269] ,)
        (NNP:[270..276] Kyushu) (NNP:[277..287] University) (,:[287..288] ,)
        (NNP:[289..296] Fukuoka) (,:[296..297] ,) (NNP:[299..304] Japan)
        (.:[304..305] .)))

;sentence 3 Span:309..539
;Adenocarcinoma of the lung obtained at surgical resection was examined for 
;mutation at codons 12, 13, and 61 of the oncogenes K-ras, H-ras, and N-ras, 
;using polymerase chain reaction and oligonucleotide hybridization
;techniques.
;[309..335]:malignancy:"Adenocarcinoma of the lung"
;[385..393]:variation-event:"mutation"
;[397..406]:variation-location:"codons 12"
;[397..403]...[416..418]:variation-location:"codons"..."61"
;[397..403]...[408..410]:variation-location:"codons"..."13"
;[436..441]:gene-rna:"K-ras"
;[443..448]:gene-rna:"H-ras"
;[454..459]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-3
      (NP
        (NP (NN:[309..323] Adenocarcinoma))
        (PP (IN:[324..326] of)
          (NP (DT:[327..330] the) (NN:[331..335] lung))))
      (VP (VBN:[336..344] obtained)
        (NP (-NONE-:[344..344] *))
        (PP (IN:[345..347] at)
          (NP (JJ:[348..356] surgical) (NN:[357..366] resection)))))
    (VP (VBD:[367..370] was)
      (VP (VBN:[371..379] examined)
        (NP-3 (-NONE-:[379..379] *))
        (PP (IN:[380..383] for)
          (NP (NN:[385..393] mutation)))
        (PP-LOC (IN:[394..396] at)
          (NP
            (NP
              (NP
                (NML-2 (NNS:[397..403] codons))
                (CD:[404..406] 12))
              (,:[406..407] ,)
              (NP
                (NML-2 (-NONE-:[407..407] *P*))
                (CD:[408..410] 13))
              (,:[410..411] ,) (CC:[412..415] and)
              (NP
                (NML-2 (-NONE-:[415..415] *P*))
                (CD:[416..418] 61)))
            (PP (IN:[419..421] of)
              (NP
                (NP (DT:[422..425] the) (NNS:[426..435] oncogenes))
                (NP (NN:[436..441] K-ras) (,:[441..442] ,) (NN:[443..448] H-ras)
                    (,:[448..449] ,) (CC:[450..453] and) (NN:[454..459] N-ras))))))
        (,:[459..460] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[460..460] *))
          (VP (VBG:[462..467] using)
            (NP
              (NP
                (NML (NN:[468..478] polymerase) (NN:[479..484] chain)
                     (NN:[485..493] reaction))
                (NML-1 (-NONE-:[493..493] *P*)))
              (CC:[494..497] and)
              (NP
                (NML (NN:[498..513] oligonucleotide)
                     (NN:[514..527] hybridization))
                (NML-1 (NNS:[528..538] techniques))))))))
    (.:[538..539] .)))

;sentence 4 Span:541..691
;The mutation was detected in 18 of the 115 cases (15.7%), and 15 of 18 were
;at  codon 12, 2 were at codon 13 of K-ras, and 1 was at codon 61 of N-ras.
;[545..553]:variation-event:"mutation"
;[621..629]:variation-location:"codon 12"
;[641..649]:variation-location:"codon 13"
;[653..658]:gene-rna:"K-ras"
;[673..681]:variation-location:"codon 61"
;[685..690]:gene-rna:"N-ras"
(SENT
  (S
    (S
      (S
        (NP-SBJ-1 (DT:[541..544] The) (NN:[545..553] mutation))
        (VP (VBD:[554..557] was)
          (VP (VBN:[558..566] detected)
            (NP-1 (-NONE-:[566..566] *))
            (PP (IN:[567..569] in)
              (NP
                (NP (CD:[570..572] 18))
                (PP (IN:[573..575] of)
                  (NP (DT:[576..579] the) (CD:[580..583] 115)
                      (NNS:[584..589] cases)
                    (PRN (-LRB-:[590..591] -LRB-)
                      (NP (CD:[591..595] 15.7) (NN:[595..596] %))
                      (-RRB-:[596..597] -RRB-)))))))))
      (,:[597..598] ,) (CC:[599..602] and)
      (S
        (S
          (NP-SBJ
            (NP (CD:[603..605] 15))
            (PP (IN:[606..608] of)
              (NP (CD:[609..611] 18))))
          (VP (VBD:[612..616] were)
            (PP-LOC-PRD (IN:[617..619] at)
              (NP (NN:[621..626] codon) (CD:[627..629] 12)))))
        (,:[629..630] ,)
        (S
          (NP-SBJ (CD:[631..632] 2))
          (VP (VBD:[633..637] were)
            (PP-LOC-PRD (IN:[638..640] at)
              (NP
                (NP (NN:[641..646] codon) (CD:[647..649] 13))
                (PP (IN:[650..652] of)
                  (NP (NN:[653..658] K-ras)))))))
        (,:[658..659] ,) (CC:[660..663] and)
        (S
          (NP-SBJ (CD:[664..665] 1))
          (VP (VBD:[666..669] was)
            (PP-LOC-PRD (IN:[670..672] at)
              (NP
                (NP (NN:[673..678] codon) (CD:[679..681] 61))
                (PP (IN:[682..684] of)
                  (NP (NN:[685..690] N-ras)))))))))
    (.:[690..691] .)))

;sentence 5 Span:692..731
;G to T  transversions were most common.
;[692..693]:variation-state-original:"G"
;[697..698]:variation-state-altered:"T"
;[700..713]:variation-type:"transversions"
(SENT
  (S
    (NP-SBJ
      (NML
        (NML (NN:[692..693] G))
        (PP (TO:[694..696] to)
          (NP (NN:[697..698] T))))
      (NNS:[700..713] transversions))
    (VP (VBD:[714..718] were)
      (ADJP-PRD (RBS:[719..723] most) (JJ:[724..730] common)))
    (.:[730..731] .)))

;sentence 6 Span:732..809
;The ras gene mutations were more frequent in the  male patients (P =
;0.0048).
;[736..739]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ (DT:[732..735] The)
      (NML (NN:[736..739] ras) (NN:[740..744] gene))
      (NNS:[745..754] mutations))
    (VP (VBD:[755..759] were)
      (ADJP-PRD (RBR:[760..764] more) (JJ:[765..773] frequent))
      (PP-LOC (IN:[774..776] in)
        (NP (DT:[777..780] the) (JJ:[782..786] male) (NNS:[787..795] patients)))
      (PRN (-LRB-:[796..797] -LRB-)
        (S
          (NP-SBJ (NN:[797..798] P))
          (PP (SYM:[799..800] =)
            (NP (CD:[801..807] 0.0048))))
        (-RRB-:[807..808] -RRB-)))
    (.:[808..809] .)))

;sentence 7 Span:810..992
;No significant differences were found to be related  to stage of the disease
;or tumor-nodes-metastases classification between  positive and negative
;groups of the ras gene mutations.
;[973..976]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-2 (DT:[810..812] No) (JJ:[813..824] significant)
              (NNS:[825..836] differences))
    (VP (VBD:[837..841] were)
      (VP (VBN:[842..847] found)
        (S
          (NP-SBJ-2 (-NONE-:[847..847] *))
          (VP (TO:[848..850] to)
            (VP (VB:[851..853] be)
              (VP (JJ:[854..861] related)
                (NP-2 (-NONE-:[861..861] *))
                (PP-CLR (TO:[863..865] to)
                  (NP
                    (NP
                      (NP (NN:[866..871] stage))
                      (PP (IN:[872..874] of)
                        (NP (DT:[875..878] the) (NN:[879..886] disease))))
                    (CC:[887..889] or)
                    (NP
                      (NML (NN:[890..895] tumor) (HYPH:[895..896] -)
                           (NNS:[896..901] nodes) (HYPH:[901..902] -)
                           (NNS:[902..912] metastases))
                      (NN:[913..927] classification))))
                (PP (IN:[928..935] between)
                  (NP
                    (NP
                      (NP (JJ:[937..945] positive)
                        (NML-1 (-NONE-:[945..945] *P*)))
                      (CC:[946..949] and)
                      (NP (JJ:[950..958] negative)
                        (NML-1 (NNS:[959..965] groups))))
                    (PP (IN:[966..968] of)
                      (NP (DT:[969..972] the)
                        (NML (NN:[973..976] ras) (NN:[977..981] gene))
                        (NNS:[982..991] mutations)))))))))))
    (.:[991..992] .)))

;sentence 8 Span:993..1068
;A history of tobacco use  was not always a factor contributing to mutation.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[993..994] A) (NN:[995..1002] history))
      (PP (IN:[1003..1005] of)
        (NP (NN:[1006..1013] tobacco) (NN:[1014..1017] use))))
    (VP (VBD:[1019..1022] was) (RB:[1023..1026] not)
      (ADVP-TMP (RB:[1027..1033] always))
      (NP-PRD
        (NP (DT:[1034..1035] a) (NN:[1036..1042] factor))
        (VP (VBG:[1043..1055] contributing)
          (PP-CLR (TO:[1056..1058] to)
            (NP (NN:[1059..1067] mutation))))))
    (.:[1067..1068] .)))

;sentence 9 Span:1069..1303
;Of the completely resected  group without lymph node metastasis, the 5-year
;survival rate in the  ras-positive group was 53.3%, which was significantly
;poorer than the 83.6%  survival rate in the ras-negative group (P less than
;0.05).
;[1111..1132]:malignancy:"lymph node metastasis"
;[1167..1170]:gene-rna:"ras"
;[1265..1268]:gene-rna:"ras"
(SENT
  (S
    (PP (IN:[1069..1071] Of)
      (NP
        (NP (DT:[1072..1075] the)
          (ADJP (RB:[1076..1086] completely) (VBN:[1087..1095] resected))
          (NN:[1097..1102] group))
        (PP (IN:[1103..1110] without)
          (NP
            (NML (NN:[1111..1116] lymph) (NN:[1117..1121] node))
            (NN:[1122..1132] metastasis)))))
    (,:[1132..1133] ,)
    (NP-SBJ
      (NP (DT:[1134..1137] the)
        (NML (CD:[1138..1139] 5) (HYPH:[1139..1140] -) (NN:[1140..1144] year))
        (NN:[1145..1153] survival) (NN:[1154..1158] rate))
      (PP (IN:[1159..1161] in)
        (NP (DT:[1162..1165] the)
          (ADJP (NN:[1167..1170] ras) (HYPH:[1170..1171] -)
                (JJ:[1171..1179] positive))
          (NN:[1180..1185] group))))
    (VP (VBD:[1186..1189] was)
      (NP-PRD
        (NP (CD:[1190..1194] 53.3) (NN:[1194..1195] %))
        (,:[1195..1196] ,)
        (SBAR
          (WHNP-1 (WDT:[1197..1202] which))
          (S
            (NP-SBJ-1 (-NONE-:[1202..1202] *T*))
            (VP (VBD:[1203..1206] was)
              (ADJP-PRD
                (ADJP (RB:[1207..1220] significantly) (JJR:[1221..1227] poorer))
                (PP (IN:[1228..1232] than)
                  (NP
                    (NP (DT:[1233..1236] the)
                      (NML (CD:[1237..1241] 83.6) (NN:[1241..1242] %))
                      (NN:[1244..1252] survival) (NN:[1253..1257] rate))
                    (PP (IN:[1258..1260] in)
                      (NP (DT:[1261..1264] the)
                        (ADJP (NN:[1265..1268] ras) (HYPH:[1268..1269] -)
                              (JJ:[1269..1277] negative))
                        (NN:[1278..1283] group)))
                    (PRN (-LRB-:[1284..1285] -LRB-)
                      (S
                        (NP-SBJ (NN:[1285..1286] P))
                        (ADJP-PRD (JJR:[1287..1291] less)
                          (PP (IN:[1292..1296] than)
                            (NP (CD:[1297..1301] 0.05)))))
                      (-RRB-:[1301..1302] -RRB-))))))))))
    (.:[1302..1303] .)))

;sentence 10 Span:1304..1427
;Our findings suggest  that ras gene mutations may be prognostic, especially
;in the early stage  adenocarcinoma of the lung.
;[1331..1334]:gene-rna:"ras"
;[1387..1426]:malignancy:"early stage  adenocarcinoma of the lung"
(SENT
  (S
    (NP-SBJ (PRP$:[1304..1307] Our) (NNS:[1308..1316] findings))
    (VP (VBP:[1317..1324] suggest)
      (SBAR (IN:[1326..1330] that)
        (S
          (NP-SBJ (NN:[1331..1334] ras) (NN:[1335..1339] gene)
                  (NNS:[1340..1349] mutations))
          (VP (MD:[1350..1353] may)
            (VP (VB:[1354..1356] be)
              (ADJP-PRD (JJ:[1357..1367] prognostic))
              (,:[1367..1368] ,)
              (PP
                (ADVP (RB:[1369..1379] especially))
                (IN:[1380..1382] in)
                (NP
                  (NP (DT:[1383..1386] the)
                    (ADJP (JJ:[1387..1392] early) (NN:[1393..1398] stage))
                    (NN:[1400..1414] adenocarcinoma))
                  (PP (IN:[1415..1417] of)
                    (NP (DT:[1418..1421] the) (NN:[1422..1426] lung))))))))))
    (.:[1426..1427] .)))

;section 11 Span:1431..1475
;PMID: 1581907 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1431..1435] PMID) (::[1435..1436] :) (CD:[1437..1444] 1581907)
        (NN:[1445..1446] -LSB-) (NNP:[1446..1452] PubMed) (::[1453..1454] -)
        (NN:[1455..1462] indexed) (IN:[1463..1466] for)
        (NNP:[1467..1475] MEDLINE-RSB-)))
